B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Home/Insights/Product comparison
Product comparison

Factor VIII vs PCC: what's the difference

Both are plasma-derived clotting products, and both are lyophilised with solvent. But one is a single coagulation factor and the other is a four-factor complex — and that difference decides which one belongs on your tender line.

Two plasma-derived products, one shared manufacturing platform, and a procurement mistake that is easy to make: treating human coagulation factor VIII (FVIII) and prothrombin complex concentrate (PCC) as if they were two strengths of the same clotting product. They are not. A buyer who merges the two lines, or who accepts a quotation that swaps one for the other, has ordered a product that corrects a different part of the coagulation cascade than the tender specifies.

This comparison is written for licensed importers, distributors and tender authorities — the people who have to put the right clotting product on the right line, with the right approval number, and hold the paperwork to prove it. It describes what each product is and how they differ, and ends with a decision guide for the procurement side.

The one-sentence difference

Factor VIII is a single coagulation factor — one protein, concentrated to treat a specific factor deficiency. PCC is a prothrombin complex — a four-factor preparation containing factors II, VII, IX and X, fractionated together to support the broader coagulation cascade. FVIII is one factor; PCC is four factors.

Side-by-side comparison

Dimension Factor VIII PCC
What it is Single coagulation factor concentrate (factor VIII) Four-factor prothrombin complex (factors II, VII, IX, X)
Source Fractionated from pooled human plasma Fractionated from pooled human plasma
Primary use Haemophilia A and factor VIII deficiency Prothrombin-complex indications, including anticoagulation reversal
Presentation 200 IU 400 IU
Dosage form Powder and solvent for solution for injection Powder and solvent for solution for injection
Storage 2–8 °C, protected from light 2–8 °C, protected from light
Shelf life 36 months 36 months
Approval number NMPA S20220023 NMPA S20200025
Manufacturer China Resources Boya China Resources Boya

The approval numbers make the point in a single line: Factor VIII and PCC carry different 国药准字 numbers because they are different registered products. A quotation that presents one number against the other product's line is a mismatch, not a substitution.

Why the difference matters at procurement

The distinction is not academic, and it shows up in three places the buying side has to get right.

Separate tender lines

Factor VIII and PCC are specified for different clinical indications, so they appear as separate lines in a tender and in the essential-medicine and reimbursement frameworks of most markets. They are not interchangeable within a line, and they are not fungible units of "clotting factor".

Separate registration dossiers

Each product holds its own registration certificate and its own batch release pathway. The dossier that registers Factor VIII does not register PCC, and the import licence in the destination market names the specific product. Mixing the two at the dossier stage delays the whole file.

Same logistics, different paperwork

Both are lyophilised and move at 2–8 °C, protected from light, so a single validated cold chain can serve both. But the batch release certificate, the certificate of analysis and the approval reference are product-specific. One cold chain, two document sets.

How to decide which one you need

The decision belongs to the specification, not to the buyer's preference. The question that resolves it is the clinical indication named in the tender or the purchase request.

  • If the requirement names haemophilia A or factor VIII deficiency, the line is Factor VIII.
  • If the requirement names a prothrombin-complex indication or anticoagulation reversal, the line is PCC.
  • If the requirement is ambiguous, stop and ask for the indication before quoting — the two products are not alternatives, and guessing is how a wrong order is placed.

Where the two genuinely do overlap is on the supplier side: both products come from the same manufacturer under the same export mandate, so a single channel can cover both lines without splitting the file.

Frequently asked questions

Are Factor VIII and PCC the same thing?

No. Factor VIII is a single coagulation factor concentrate, while PCC is a four-factor preparation containing factors II, VII, IX and X. They correct different parts of the coagulation cascade and are not interchangeable.

Which one should a hospital tender specify?

It depends on the clinical indication, not on price. Factor VIII is specified for haemophilia A and factor VIII deficiency; PCC is specified for reversal of vitamin K antagonist anticoagulation and related prothrombin-complex indications. They are separate tender lines and should not be merged.

Do Factor VIII and PCC need the same cold chain?

Yes, both are lyophilised powders with solvent for reconstitution, shipped and stored at 2–8 °C protected from light, and must not be frozen. The same validated cold chain can serve both.

Are the presentations the same?

No. The Factor VIII we supply is presented at 200 IU, while the PCC is presented at 400 IU. Strengths and international-unit labelling differ, so the two lines must be quoted separately.

Can one supplier provide both?

Yes. Both products are supplied by China Resources Boya under wanyoda's export mandate, so a single manufacturer and a single export channel can cover both tender lines.

Where to go next

Sourcing

Specify the right product on the right line.

Tell us the indication and destination market, and we will confirm the matching product, approval reference and registration dossier.